Martin Kaiser

@MyMKaiser

Professor of Haematology/Myeloma researcher; genetics & imaging for patient-centric care. Vice-chair UK Myeloma Research Alliance (UKMRA). Academic nomad.

linked, the sky, etc Joined July 2017

1.8K Following 1.8K Followers 1.2K Posts

Latest posts 5

Martin Kaiser @MyMKaiser 4d

Fantastic podcast about the #UKMRA OPTIMUM MUKnine results. We are working hard on making this treatment available to high-risk patients on the NHS - but it is very difficult in a public payer system to translate academic research (incl UK patients' trust and faith) into practice

IACH Verified account @TheIACH 5d

→ Tune in to the latest IACH News podcast:

OPTIMUM/MUKnine: Can intensified, risk-adapted therapy overcome high-risk multiple myeloma?
⭣
on.soundcloud.com/9B5qJsit0RdsN0…

Click for the abstract ⬎
pubmed.ncbi.nlm.nih.gov/42705255/

@Mohty_EBMT

View quoted post on X

Martin Kaiser @MyMKaiser Mar 29

Precision medicine in #myeloma demands precision imaging: is whole body MRI #WBMRI the solution?
@ProfMessiou
doi.org/10.1186/s40644…

link.springer.com Precision medicine in myeloma demands precision imaging: is whole body MRI the solution? Cancer Imaging - Outcomes for patients with multiple myeloma have improved substantially over the past two decades, with median overall survival more than doubling in many cohorts. Management of...

Martin Kaiser @MyMKaiser May 22, 2025

Looking forward to speaking on treatment of High-risk #myeloma at @EHA_Hematology conference in Milano in June - many thanks @Myeloma_Society and EHA for invite. In the meantime, hope people might enjoy our @BritSocHaem podcast on this topic:
podbean.com/ew/pb-2734e-17…

Martin Kaiser @MyMKaiser Mar 7, 2025

Very happy to see our global collaborative effort published in @JCO_ASCO : co-occurrence of ≥2 HRCAs is consistently associated with highest unmet need in NDMM and RRMM, across time and treatment modalities.
ascopubs.org/doi/10.1200/JC…

ascopubs.org Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/... PURPOSESurvival for patients with multiple myeloma (MM) has improved but outcomes remain heterogeneous. Consistent diagnostic identification of high-risk disease is desirable to address unmet patient...

Martin Kaiser @MyMKaiser Jan 7, 2025

Nice @ESHaematology - instead of removing access in time for the New Year, access is made free for all - have a look if you are interested in #myeloma (😉 @ASH_hematology - inspirational?)

ESH (Haematology) @ESHaematology Jan 6, 2025

🔔 BREAKING NEWS!
The on-demand content of #ESHMM2024 is available FOR FREE on our ESH eLearning Centre ➡ bit.ly/4a8j9IA
7th Translational Research Conference
MULTIPLE #MYELOMA
Chairs: H. Goldschmidt, @MyMKaiser, @SLentzsch #ESHCONFERENCES #ESHELEARNING #MMsm

View quoted post on X